Literature DB >> 9671397

Determinants for transformation induced by the Axl receptor tyrosine kinase.

A Burchert1, E C Attar, P McCloskey, Y W Fridell, E T Liu.   

Abstract

The Axl receptor tyrosine kinase is a transforming oncogene in NIH3T3 cells. In order to define structural requirements of the Axl receptor necessary for transformation we passaged recombinant retroviruses carrying the axl cDNA in NIH3T3 cells, generating randomly mutated axl variants. Using this strategy, we have isolated three axl viral strains (1B1, SV8, and FFa4) that show augmented 3T3 cell transforming capacity associated with elevated p140Axl. Upon sequencing, the 1B1 and SV8 proviruses possessed only silent mutations, making p140Axl overexpression the most likely explanation for their increased transformation activity. However, the characterization of FFa4 revealed a deletion of sequences encoding the carboxy-terminal 45 amino acids leading to the generation of a chimeric transcript comprised of a truncated Axl receptor with a segment of the 3' UTR region. Mutational analysis revealed that the transforming activity of FFa4 was specific to the formation of the chimeric receptor rather than to the carboxyl-terminal truncation. Intriguingly, none of the viral strains were able to transform the murine cell lines NR-6 and 32D despite equivalent expression of surface p140Axl protein. Further analysis showed that Axl's transforming potential is dependent on the host cell type, the presence of a putative pp190 as a facilitator for transformation, and the level of p140Axl expression. Taken together, these results underscore the complexity of Axl biology which is dependent on receptor stoichiometry and the cellular background.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671397     DOI: 10.1038/sj.onc.1201865

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control.

Authors:  Vadim Budagian; Elena Bulanova; Zane Orinska; Lutz Thon; Uwe Mamat; Paola Bellosta; Claudio Basilico; Dieter Adam; Ralf Paus; Silvia Bulfone-Paus
Journal:  EMBO J       Date:  2005-11-24       Impact factor: 11.598

2.  A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation.

Authors:  D Besser; J F Bromberg; J E Darnell; H Hanafusa
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Gas6 induces growth, beta-catenin stabilization, and T-cell factor transcriptional activation in contact-inhibited C57 mammary cells.

Authors:  S Goruppi; C Chiaruttini; M E Ruaro; B Varnum; C Schneider
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 4.  Axl-dependent signalling: a clinical update.

Authors:  Vyacheslav A Korshunov
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

5.  Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion.

Authors:  Afnan Abu-Thuraia; Rosemarie Gauthier; Rony Chidiac; Yoshinori Fukui; Robert A Screaton; Jean-Philippe Gratton; Jean-François Côté
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

6.  Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity.

Authors:  W P Lee; Y Liao; D Robinson; H J Kung; E T Liu; M C Hung
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

7.  Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.

Authors:  Pavel A Levin; Rolf A Brekken; Lauren Averett Byers; John V Heymach; David E Gerber
Journal:  J Thorac Oncol       Date:  2016-04-26       Impact factor: 15.609

Review 8.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

9.  AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Authors:  Haley D Axelrod; Kenneth C Valkenburg; Sarah R Amend; Jessica L Hicks; Princy Parsana; Gonzalo Torga; Angelo M DeMarzo; Kenneth J Pienta
Journal:  Mol Cancer Res       Date:  2018-10-05       Impact factor: 5.852

10.  Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.

Authors:  Khanh-Quynh N Nguyen; Wen-I Tsou; Daniel A Calarese; Stanley G Kimani; Sukhwinder Singh; Shelly Hsieh; Yongzhang Liu; Bin Lu; Yi Wu; Scott J Garforth; Steve C Almo; Sergei V Kotenko; Raymond B Birge
Journal:  J Biol Chem       Date:  2014-07-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.